Lithium and Memory: Experts Discuss Low-Dose Findings in Older Adults with MCI

19 Mar 20264 min read0 viewsVerified Feed

GIST

Could a decades-old treatment for bipolar disorder be the key to slowing memory loss that comes with age? Researchers from the University of Pittsburgh think so.

Led by Ariel Gildengers , professor of psychiatry at Pitt and a geriatric psychiatrist at UPMC , the researchers launched a 2-year exploratory clinical trial to investigate the effects of low-dose oral lithium on older adults (ages 60+) with mild cognitive impairment (MCI). Lithium is a mood stabilizer and gold-standard long-term treatment for bipolar disorder that helps manage episodes of acute mania and depression , and reduces suicide risk.

The doses used in this study, however, were very small doses — much lower than those used for bipolar disorder. Among 80 participants, those who received a daily low-dose lithium carbonate showed a slower rate of decline in verbal memory, the ability to remember and recall words and sentences, compared to those who were on a placebo.

The fact that such low doses of lithium were safe and well-tolerated makes these findings encouraging — smaller doses may confer cognitive benefits with fewer side effects.

Clinical Editorial

Context and study framework

A two-year exploratory clinical trial was conducted by researchers at the University of Pittsburgh, led by Ariel Gildengers, focusing on older adults aged 60 years and above with mild cognitive impairment (MCI).
The investigation evaluated the effects of very low-dose oral lithium carbonate on cognitive trajectories in this population, comparing against a placebo control.
The initiative sought to determine whether a decades-old mood stabilizer, traditionally used in bipolar disorder, might influence memory decline associated with aging, particularly in the context of MCI.

Design, population, and intervention specifics

Sample size and structure: 80 participants were enrolled and randomized to receive either daily low-dose lithium carbonate or placebo over a two-year period.
Intervention intensity: Doses employed were substantially lower than those used for psychiatric indications such as bipolar disorder, reflecting a safety-oriented, exploratory approach in an older cohort.
Primary cognitive domain assessed: Verbal memory, operationalized as the ability to remember and recall words and sentences, was the key outcome used to gauge cognitive change over time.

Key findings with explicit limitations

Additional research is needed to clarify these aspects.

Cognitive signal: Participants receiving the low-dose lithium demonstrated a slower rate of decline in verbal memory relative to the placebo group over the two-year horizon.
Safety and tolerability: The low-dose regimen was characterized as safe and well tolerated within this study framework, implying a favorable safety profile at these concentrations in an older population.
Amyloid interaction: A stronger neuroprotective signal emerged among participants who tested positive for amyloid-beta, suggesting a potential interaction between amyloid status and lithium’s neurocognitive effects in this cohort.
Interpretation caveats: The trial is explicitly described as a proof-of-concept study, meaning that while results are encouraging, they are not definitive and require confirmation in larger, more definitive trials before any clinical recommendations could be issued.
Long-term durability and dosage optimization: The study did not establish whether the observed cognitive benefits persist beyond two years, nor did it identify an optimal dose (“sweet spot”) balancing efficacy with risks to renal or thyroid health.

Mechanistic considerations and interpretive themes

In particular, it may inhibit glycogen synthase kinase-3 (GSK-3), a kinase implicated in tau phosphorylation and neuronal dysfunction in Alzheimer’s disease.

Lithium’s influence on brain-derived neurotrophic factor (BDNF) signaling pathways is also noted as potentially supporting neuronal survival and plasticity.

However, there is an emphasis on recognizing that lithium’s effects likely involve both mood-related and direct neurobiological mechanisms, with the potential to disentangle these components in future trials by collecting mood, cognitive, and biomarker data in parallel.

Proposed neurobiological pathways: Lithium may exert effects across multiple brain pathways beyond mood stabilization.
Amyloid-related considerations: Preclinical and translational work cited in the discussion suggests lithium could mitigate some toxic consequences associated with amyloid proteins, aligning with the observed stronger signal in amyloid-positive participants.
Mood-cognition interplay: The discussion acknowledges that mood stabilization, sleep quality, and stress reactivity may indirectly benefit cognition in individuals with MCI, where mood disorders can exacerbate cognitive performance.

Context, practicality, and open questions

Medical supervision and regular laboratory monitoring would be essential if broader exploration proceeds in the future.

Clinical translation: While the findings introduce an intriguing possibility, the article stresses that lithium is not yet proven as a brain-health intervention in aging or in specific dementia etiologies.
Diagnostic scope: It remains unclear which subtypes of cognitive decline—such as Alzheimer’s disease versus vascular cognitive impairment—would most benefit from lithium, if any at all, beyond the MCI stage.
Research gaps: Uncertainty persists regarding the durability of benefit over longer periods, the precise dosing range that balances cognitive gains against potential renal or thyroid adverse effects, and the delineation of mood-related versus neurobiological contributions to any observed effects.

Editorial note on reporting limits

Consequently, quantitative interpretation is constrained to the qualitative statements presented: a slower verbal-memory decline with low-dose lithium, general safety/tolerability, and amplified signal among amyloid-positive participants.

The article explicitly characterizes the work as a preliminary proof-of-concept study, underscoring the need for larger, rigorous trials before clinical recommendations can be made.